About Us

We have been in the market under various names for the past 16 years, the name changes follow market and safety needs. This is the first time we introduce a web page mostly to elucidate the condition of the AAS market as it stands and make clear to consumers that when you are buying into a brand you are essentially investing in the people behind it. We do this for several reasons besides the obvious:

  • We enjoy it, we like the complexities and problem solving of the manufacture and marketing of our products. 
  • We believe that people should have the option to purchase products that are correctly dosed, meticulously sterilised and be void of cross contaminations, this particular aspect of our work ethic comes from serious issues one of us had with using a (quite famous back in 2003 brand) product that was marketed as oxandrolone and was accidentally contaminated with fluoxymesterone.
  • We use them ourselves.

The AAS market has gotten to a point where engineering sophistication and marketing methods have become much more important than the actual product itself. You have to understand that there are no more “pharmaceutical grade” products on the market. We do not pretend to be a pharma factory that has invested tens of millions to comply with health organisations around the world and then puts all that at risk by manufacturing and selling AAS. You should be suspicious of anyone that suggests they are. Even in developing countries the regulations for the production of injectable pharmaceuticals are very stringent because those drugs are meant to be given to sick or immunocompromised individuals, something that demands extreme sterility measures. Its nonsensical for someone that has the money to do that to risk it for the relatively small AAS market.  

As of today most AAS are manufactured in two major ways 1) small UG labs that acquire raw materials from overseas and then formulate them into, usualy, 10 ml vials and 2) larger UG labs based mostly in developing countries some of which work in a mafia like way with a degree of the hosting states tolerance. The problem with manufacturers like those is that they pay their workers extremely low wages and thus the incentive for going through the proper steps of ensuing the products quality is non existent while on the other hand the motivation for substituting raw materials huge (this includes all current ampoule ranges in the market).

For example polish and moldovan manufacturers of ampoules charge something like 50 cents per ampoule plus the raw material and have a minimum order of 10.000 ampoules per raw material. As you can understand substituting drostanolone for methenolone gives a huge profit potential to the cost of the consumer.  

We have been at both those extremes and we have concluded that something in the middle is the best solution for both producers and consumers. In the end our products are somewhat more expensive mostly because we take care and spend man hours into ensuring quality.

With respect

Jacob PhD biology
Harry MsC mechanical engineering
Gus Bachelor of sports physiology